---
title: VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis
nct_id: NCT05655299
overall_status: TERMINATED
phase: PHASE2
sponsor: Ventyx Biosciences, Inc
study_type: INTERVENTIONAL
primary_condition: Psoriasis
countries: United States, Canada, Poland
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05655299.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05655299"
ct_last_update_post_date: 2024-09-19
last_seen_at: "2026-05-12T06:36:48.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis

**Official Title:** A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Participants With Moderate to Severe Psoriasis

**NCT ID:** [NCT05655299](https://clinicaltrials.gov/study/NCT05655299)

## Key Facts

- **Status:** TERMINATED
- **Why Stopped:** Business Decision
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 222
- **Lead Sponsor:** Ventyx Biosciences, Inc
- **Conditions:** Psoriasis
- **Start Date:** 2022-11-17
- **Completion Date:** 2023-12-20
- **CT.gov Last Update:** 2024-09-19

## Brief Summary

This is a study to understand if taking VTX958 is safe and effective in participants diagnosed with moderate to severe psoriasis (PsO). Approximately 200 patients will take VTX958 Dose A, VTX958 Dose B, VTX958 Dose C, VTX958 Dose D, or placebo.

The study consists of a 30-day Screening Period (to see if a participant qualifies for the study), a 16-week double-blind period (a participant receives active Dose A, Dose B, Dose C, Dose D, or placebo), a 16-week Long Term Extension (LTE) period, a 36-week Open Label Extension (OLE) period and a 4-week Follow-Up Period. The maximal duration of treatment will be approximately 16 months.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Male or female participant aged 18 years or older.
* History of primarily plaque psoriasis for at least 6 months prior to the screening visit.
* Has had stable psoriasis conditions for at least 3 months before screening.
* Has moderate to severe plaque psoriasis as defined by a PASI score of ≥ 12 and an sPGA score of ≥ 3 at screening and Day 1.
* Has plaque psoriasis covering ≥ 10% of the total BSA at screening and Day 1.
* Deemed by the investigator to be eligible for phototherapy or systemic therapy.
* Females of childbearing potential must agree to use a highly effective contraceptive method from at least 4 weeks prior to Day 1 until at least 4 weeks after the last dose of study product.

Exclusion Criteria:

* Female who is breastfeeding, pregnant, lactating, or who is planning to become pregnant during the study.
* Has evidence of erythrodermic, pustular, predominantly inverse or guttate psoriasis, or drug-induced psoriasis.
* History of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments.
* Participant is known to have immune deficiency or is immunocompromised.
* Has immune-mediated conditions commonly associated with psoriasis, such as psoriatic arthritis, active uveitis, inflammatory bowel disease, that currently require systemic treatment (including corticosteroids, immunosuppressants, or biologics).

Note: Participants with immune-mediated conditions commonly associated with psoriasis that do not require systemic treatment may be included in the study.

* Has used any topical medication that could affect psoriasis (including corticosteroids, retinoids, vitamin D analogues \[such as calcipotriol\], Janus kinase \[JAK\] inhibitors, or tar) within 2 weeks prior to Day 1.
* Has used any systemic treatment that could affect psoriasis (including corticosteroids, oral retinoids, immunosuppressive medication, anakinra, methotrexate, cyclosporine, oral JAK inhibitors, or apremilast) within 4 weeks prior to Day 1.

Note: Intranasal corticosteroids and inhaled corticosteroids are allowed. Eye and ear drops containing corticosteroids are also allowed.

* Participant has received any ultraviolet B (UVB) phototherapy (including tanning beds) or excimer laser within 4 weeks prior to Day 1.
* Participant has had psoralen and ultraviolet A (PUVA) treatment within 4 weeks prior to Day 1.
* Participant has received treatment with an investigational or marketed TYK2 inhibitor.
```

## Arms

- **VTX958 Dose A** (EXPERIMENTAL)
- **VTX958 Dose B** (EXPERIMENTAL)
- **VTX958 Dose C** (EXPERIMENTAL)
- **VTX958 Dose D** (EXPERIMENTAL)
- **Placebo** (PLACEBO_COMPARATOR)

## Interventions

- **VTX958 Dose A** (DRUG) — Dose A
- **VTX958 Dose B** (DRUG) — Dose B
- **VTX958 Dose C** (DRUG) — Dose C
- **VTX958 Dose D** (DRUG) — Dose D
- **Placebo** (DRUG) — Placebo

## Primary Outcomes

- **Psoriasis Area and Severity Index (PASI) Efficacy at 16 weeks** _(time frame: Day 1 of Placebo-controlled treatment period to week 16)_ — Proportion of subjects achieving PASI-75 at Week 16
- **Adverse Event (AE) / Serious Adverse Event (SAE) Incidence Rate through study completion** _(time frame: Screening through study completion, up to 76 weeks)_ — Incidence of AEs and SAEs

## Secondary Outcomes

- **Static Physician's Global Assessment (sPGA) Efficacy at 16 weeks** _(time frame: Day 1 of Placebo-controlled treatment period to week 16)_
- **PASI Efficacy at 16 weeks** _(time frame: Day 1 of Placebo-controlled treatment period to week 16)_
- **PASI Efficacy at 16 weeks** _(time frame: Day 1 of Placebo-controlled treatment period to week 16)_
- **PASI Efficacy at 16 weeks** _(time frame: Day 1 of Placebo-controlled treatment period to week 16)_
- **Dermatology Life Quality Index (DLQI) Efficacy at 16 weeks** _(time frame: Day 1 of Placebo-controlled treatment period to week 16)_
- **Body Surface Area (BSA) Efficacy at 16 weeks** _(time frame: Day 1 of Placebo-controlled treatment period to week 16)_

## Locations (63)

- Local Site # 840012, Birmingham, Alabama, United States
- Local Site # 840006, Birmingham, Alabama, United States
- Local Site # 840028, Phoenix, Arizona, United States
- Local Site # 840032, Bryant, Arkansas, United States
- Local Site # 840041, North Little Rock, Arkansas, United States
- Local Site # 840031, Fountain Valley, California, United States
- Local Site # 840026, Lomita, California, United States
- Local Site # 840019, Santa Rosa, California, United States
- Local Site # 840003, Sherman Oaks, California, United States
- Local Site # 840040, Boca Raton, Florida, United States
- Local Site # 840011, Doral, Florida, United States
- Local Site # 840023, Hialeah, Florida, United States
- Local Site # 840021, Miami Lakes, Florida, United States
- Local Site # 840044, North Miami Beach, Florida, United States
- Local Site # 840010, Ocala, Florida, United States
- Local Site # 840004, Tampa, Florida, United States
- Local Site # 840001, Tampa, Florida, United States
- Local Site # 840045, West Palm Beach, Florida, United States
- Local Site # 840029, Marietta, Georgia, United States
- Local Site # 840035, Clarksville, Indiana, United States
- Local Site # 840005, Indianapolis, Indiana, United States
- Local Site # 840030, Plainfield, Indiana, United States
- Local Site # 840013, Louisville, Kentucky, United States
- Local Site # 840022, Rockville, Maryland, United States
- Local Site # 840008, Brighton, Massachusetts, United States
- Local Site # 840016, Bay City, Michigan, United States
- Local Site # 840007, Fort Gratiot, Michigan, United States
- Local Site # 840002, Troy, Michigan, United States
- Local Site # 840034, New Brighton, Minnesota, United States
- Local Site # 840024, Saint Joseph, Missouri, United States
- Local Site # 840027, Portsmouth, New Hampshire, United States
- Local Site # 840042, Wilmington, North Carolina, United States
- Local Site # 840037, Mason, Ohio, United States
- Local Site # 840009, Portland, Oregon, United States
- Local Site # 840038, Rapid City, South Dakota, United States
- Local Site # 840015, Murfreesboro, Tennessee, United States
- Local Site # 840039, Pflugerville, Texas, United States
- Local Site # 840014, Spokane, Washington, United States
- Local Site # 124012, Fredericton, Canada
- Local Site # 124010, Mississauga, Canada
- Local Site # 124002, Montreal, Canada
- Local Site # 124004, North Bay, Canada
- Local Site # 124011, Oshawa, Canada
- Local Site # 124007, Peterborough, Canada
- Local Site # 124008, Québec, Canada
- Local Site # 124005, Toronto, Canada
- Local Site # 124006, Windsor, Canada
- Local Site # 616015, Bialystok, Poland
- Local Site # 616016, Bialystok, Poland
- Local Site # 616001, Katowice, Poland
- Local Site # 616014, Krakow, Poland
- Local Site # 616004, Lodz, Poland
- Local Site #616010, Lublin, Poland
- Local Site # 616011, Mikołów, Poland
- Local Site # 616009, Nowa Sól, Poland
- Local Site # 616003, Ostrowiec Świętokrzyski, Poland
- Local Site # 616008, Poznan, Poland
- Local Site # 616007, Szczecin, Poland
- Local Site # 616013, Szczecin, Poland
- Local Site # 616005, Warsaw, Poland
- Local Site # 616002, Wroclaw, Poland
- Local Site # 616006, Wroclaw, Poland
- Local Site # 616018, Wroclaw, Poland

## Recent Field Changes (last 30 days)

- `locations.local site # 840011|doral|florida|united states` — added _(2026-05-12)_
- `locations.local site # 840031|fountain valley|california|united states` — added _(2026-05-12)_
- `locations.local site # 840026|lomita|california|united states` — added _(2026-05-12)_
- `locations.local site # 840023|hialeah|florida|united states` — added _(2026-05-12)_
- `locations.local site # 840019|santa rosa|california|united states` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `locations.local site # 840003|sherman oaks|california|united states` — added _(2026-05-12)_
- `locations.local site # 840040|boca raton|florida|united states` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.local site # 840012|birmingham|alabama|united states` — added _(2026-05-12)_
- `locations.local site # 840006|birmingham|alabama|united states` — added _(2026-05-12)_
- `locations.local site # 840028|phoenix|arizona|united states` — added _(2026-05-12)_
- `locations.local site # 840032|bryant|arkansas|united states` — added _(2026-05-12)_
- `locations.local site # 840041|north little rock|arkansas|united states` — added _(2026-05-12)_
- `locations.local site # 840021|miami lakes|florida|united states` — added _(2026-05-12)_
- `locations.local site # 840044|north miami beach|florida|united states` — added _(2026-05-12)_
- `locations.local site # 840010|ocala|florida|united states` — added _(2026-05-12)_
- `locations.local site # 840004|tampa|florida|united states` — added _(2026-05-12)_
- `locations.local site # 840001|tampa|florida|united states` — added _(2026-05-12)_
- `locations.local site # 840045|west palm beach|florida|united states` — added _(2026-05-12)_
- `locations.local site # 840029|marietta|georgia|united states` — added _(2026-05-12)_
- `locations.local site # 840035|clarksville|indiana|united states` — added _(2026-05-12)_
- `locations.local site # 840005|indianapolis|indiana|united states` — added _(2026-05-12)_
- `locations.local site # 840030|plainfield|indiana|united states` — added _(2026-05-12)_
- `locations.local site # 840013|louisville|kentucky|united states` — added _(2026-05-12)_
- `locations.local site # 840022|rockville|maryland|united states` — added _(2026-05-12)_
- `locations.local site # 840008|brighton|massachusetts|united states` — added _(2026-05-12)_
- `locations.local site # 840016|bay city|michigan|united states` — added _(2026-05-12)_
- `locations.local site # 840007|fort gratiot|michigan|united states` — added _(2026-05-12)_
- `locations.local site # 840002|troy|michigan|united states` — added _(2026-05-12)_
- `locations.local site # 840034|new brighton|minnesota|united states` — added _(2026-05-12)_
- `locations.local site # 840024|saint joseph|missouri|united states` — added _(2026-05-12)_
- `locations.local site # 840027|portsmouth|new hampshire|united states` — added _(2026-05-12)_
- `locations.local site # 840042|wilmington|north carolina|united states` — added _(2026-05-12)_
- `locations.local site # 840037|mason|ohio|united states` — added _(2026-05-12)_
- `locations.local site # 840009|portland|oregon|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05655299.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05655299*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*